Grace Therapeutics (GRCE) Receivables (2017 - 2024)
Grace Therapeutics (GRCE) posted Receivables of $418000.0 for Q2 2024, down 44.78% sequentially from $757000.0 in Q1 2024, and down 52.87% YoY from $887000.0 in Q3 2023.
Grace Therapeutics (GRCE) Receivables (2017 - 2024) Analysis & Trends
Grace Therapeutics has reported Receivables for 8 years, with the latest figure at $418000.0 in Q2 2024.
- Quarterly Receivables fell 52.87% year-over-year to $418000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $418000.0 (down 52.87% YoY) and the FY2024 annual result came in at $757000.0, down 11.36% from the prior year.
- Receivables slipped to $418000.0 in Q2 2024 per GRCE's latest filing, from $757000.0 in the prior quarter.
- Over five years, Receivables peaked at $1.1 million in Q4 2023 and troughed at $238000.0 in Q4 2021.
- A 5-year average of $692666.7 and a median of $691000.0 in 2020 frame the typical range for Receivables.
- The sharpest annual moves came in 2021 and 2022: Receivables slumped 61.55% in 2021, then surged 226.89% in 2022.
- Over 5 years, Receivables stood at $619000.0 in 2020, then plunged by 61.55% to $238000.0 in 2021, then soared by 226.89% to $778000.0 in 2022, then jumped by 44.34% to $1.1 million in 2023, then plunged by 62.78% to $418000.0 in 2024.
- According to Business Quant data, Receivables over the past three periods registered $418000.0, $757000.0, and $1.1 million for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Grace Therapeutics | 37.72 Mn | 37.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 418,000.00 |
| Mar 31, 2024 | 757,000.00 |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | 931,000.00 |
| Jun 30, 2023 | 887,000.00 |
| Mar 31, 2023 | 854,000.00 |
| Dec 31, 2022 | 778,000.00 |
| Sep 30, 2022 | 859,000.00 |
| Jun 30, 2022 | 964,000.00 |
| Mar 31, 2022 | 559,000.00 |
| Dec 31, 2021 | 238,000.00 |
| Sep 30, 2021 | 813,000.00 |
| Jun 30, 2021 | 448,000.00 |
| Mar 31, 2021 | 543,000.00 |
| Dec 31, 2020 | 619,000.00 |
| Sep 30, 2020 | 625,000.00 |
| Jun 30, 2020 | 495,000.00 |
| Mar 31, 2020 | 557,000.00 |
| Mar 31, 2019 | 1.20 Mn |
| Mar 31, 2018 | 606,062.36 |